KCNA3 and acute myeloid leukemia: Inhibition of Kv10.1 by the potassium channel blocker astemizole, the specific anti-Kv10.1 antibody mAb56, or siRNA strongly increased apoptosis in primary AML cells and cell lines treated with chemotherapeutic agents commonly used in AML therapy, including etoposide, cytarabine, and doxorubicin [30].